IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Closed Good Friday 04-17 16:00:00 EDT

0.2650

+0.0100

+3.92%

盘后0.2650

+0.00000.00%

19:19 EDT

High0.2700	Low0.2500	Vol72.66K
Open0.2500	D1 Closing0.2550	Amplitude7.84%
Mkt Cap2.67M	Tradable Cap2.52M	Total Shares10.07M
T/O19.30K	T/O Rate0.76%	Tradable Shares9.52M
P/B0.02	ROE-6.07%	EPS-0.98
52wk High1.07	52wk Low0.1966	P/E-0.27
Dividend0.00	Div.Yield0.00	ROA-2.72%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.265,"timestamp":1744920000000,"preClose":0.255,"halted":0,"volume":72662,"hourTrading":{"tag":"盘后","latestPrice":0.265,"preClose":0.265,"latestTime":"19:19 EDT","volume":62,"amount":15.4108,"timestamp":1744931946876},"delay":0,"floatShares":9524204,"shares":10065920,"eps":-0.98,"marketStatus":"Closed Good Friday","change":0.01,"latestTime":"04-17 16:00:00 EDT","open":0.25,"high":0.27,"low":0.25,"amount":19302.0208744,"amplitude":0.078431,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.98,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.255,"preHourTrading":{"tag":"盘前","latestPrice":0.2678,"preClose":0.255,"latestTime":"09:19 EDT","volume":1243,"amount":318.24299045000004,"timestamp":1744895985915},"postHourTrading":{"tag":"盘后","latestPrice":0.265,"preClose":0.265,"latestTime":"19:19 EDT","volume":62,"amount":15.4108,"timestamp":1744931946876},"volumeRatio":1.0012418947576516,"impliedVol":0.3092,"impliedVolPercentile":0.1594},"requestUrl":"/m/hq/s/ITP","defaultTab":"news","newsList":[{"id":"2525899597","title":"Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899597","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899597?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  08, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057546/0/en/Bionano-Announces-French-Publication-of-an-Effective-Method-for-Analysis-of-Multiple-Myeloma-by-OGM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2525248895","title":"BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2525248895","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525248895?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 19:15","pubTimestamp":1744110900,"startTime":"0","endTime":"0","summary":"LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's  initiation of Phase 3 clinical trial of mezagitamab , identified from BioInvent's proprietary n-CoDeR antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia .\"We are excited to see mezagitamab progress into Phase 3 trials, marking a significant step for Takeda and our n-CoDeR platform,\" said Martin Welschof, Chief Executive Officer of BioInvent. \"This milestone not only validates the consistent high quality of drug candidates identified from our n-CoDeR antibody library, but it also highlights the success of our out-licensing strategy and its ability to drive real-world impact t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-milestone-payment-takeda-111500286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","XOMA","BOVNF","ITP","TAK","BK4199","BK4007"],"gpt_icon":0},{"id":"2524595405","title":"Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2524595405","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524595405?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 13:00","pubTimestamp":1743656400,"startTime":"0","endTime":"0","summary":"Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease. Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia. Paris, April 3, 2025. The US Food and Drug Administration  has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase  inhibitor, for two rare diseases, warm autoimmune hemolytic anemia  and IgG4-related disease . There is still a significant unmet medical need for these two rare diseases, and neither have any currently approved medicine. FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.About rilzabrutinib Rilzabrutinib is an investigational, oral, reversible, BTK inhibitor that has the potential to be a first- and best-in-class treatment of several immune-mediated diseases. BTK, expressed in B cells, mac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-rilzabrutinib-granted-orphan-050000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00BFXG1179.USD","BK4007","BK4199","ITP","SNY","BK4588"],"gpt_icon":0},{"id":"2524749829","title":"Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524749829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524749829?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:01","pubTimestamp":1743451260,"startTime":"0","endTime":"0","summary":"Conference call today, March 31, 2025 at 4:30 PM ETSAN DIEGO, March  31, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052748/0/en/Bionano-Reports-Fourth-Quarter-and-Full-Year-2024-Results-and-Provides-Revenue-Outlook-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","BK4585","LU1894683348.USD","BK4588","CMS","ITP","LU2637428348.USD","LU2500361329.USD","LU2346227817.USD","LU1894683264.USD","BK4208"],"gpt_icon":0},{"id":"2523947806","title":"CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523947806","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523947806?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:15","pubTimestamp":1743423300,"startTime":"0","endTime":"0","summary":"BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. , , a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlights for 2024.Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, \"2024 was a transformative year for CASI as we strategically pivoted our company toward the development of CID-103 for organ transplant rejection and autoimmune disease. CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection . We are encouraged by our clinical progress, achieving a milestone with the first Immune Thrombocytopenia  patient dosed in January 2025. Simultaneously, we are diligently working towards resolution of the FDA renal allograft ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/casi-pharmaceuticals-announces-fourth-quarter-121500480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","BK4139","AMR","BK4588","ITP","CTA","BK4585","CDE","BK4006","CASI","BK4199"],"gpt_icon":0},{"id":"2522372236","title":"Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522372236","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522372236?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:05","pubTimestamp":1743077100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc.  resolving patent litigation related to Rigel's product TAVALISSE . The litigation resulted from submission by Annora of an Abbreviated New Drug Application to theU.S. Food and Drug Administration seeking approval to market a generic version of TAVALISSE inthe United States. Under the terms of the settlement agreement, Annora will have a license to sell its generic product in Q2 2032 or earlier under certain circumstances. In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding TAVALISSE patents pending in New Jersey.\"The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia,\" said R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rigel-announces-settlement-agreement-resolving-120500257.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigel-announces-settlement-agreement-resolving-120500257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4199","RIGL","ITP"],"gpt_icon":0},{"id":"2522359149","title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522359149?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:38","pubTimestamp":1743021535,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4199","ITP","BK4139","CLYM"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ITP","BK4077","SLE","BK4199","CLYM"],"gpt_icon":0},{"id":"2521747672","title":"Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747672","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747672?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, and GREENWOOD, S.C., March 24, 2025  -- Bionano Genomics, Inc. and Greenwood Genetic Center  today announced a publication in Genome Research describing the first study to use optical genome mapping  to investigate the genetic landscape of neural tube defects . NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. Despite an expected genetic link in as many as 60-70% of cases, methods currently in use, including karyotyping , chromosomal microarray  and next-generation sequencing , collectively identify pathogenic gene variants in only about 8% of cases, suggesting more work is needed to better understand the underlying genetic drivers of NTDs.In this GGC study, OGM was used to provide a comprehensive, genome-wide analysis of structural variants  across a study cohort of 104 NTD cases. The key findings include:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-using-ogm-neural-tube-120000906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4199","LU0541501648.USD","NGS","LU0541502299.USD","BNGO","CMA","BK4115","BK4211","BK4179","ITP","KT","BK4585","BK4589","BK4207","BK4588","BK4575","BK4121"],"gpt_icon":0},{"id":"2520605180","title":"Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2520605180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520605180?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"Featured Scientific Session: \"Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory\", an accredited continuing medical education  session, with a panel of experts presenting research on OGM's clinical and translational applications.Dr. Adam Smith  will provide an overview of OGM’s evolution into an essential tool for hematological malignancy research and its role in research of pre- and post-natal constitutional genetic disease.Dr. Laila El-Khattabi  will share results from the CHROMAPS project, a multi-institutional European collaboration utilizing OGM to evaluate structural variations and aneuploidies in constitutional and reproductive disorders.Dr. Nikhil S. Sahajpal  will present OGM findings from three clinical research cohorts, including neural tube defects , undiagnosed rare disorders, and prenatal cases.Dr. Rashmi Kanagal-Shamanna  will showcase an integrated approach combining OGM and targeted NGS for hematologic malignancies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bionano-announces-extensive-lineup-content-120000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BVYPNW00.USD","LU2089283258.USD","LU0265550946.USD","IE00BVYPNV92.GBP","BK4121","BK4585","LU0912757837.SGD","BK4112","LU1481011671.HKD","LU0265550359.USD","LU1116320901.HKD","LU1116320737.USD","CME","LU0795875086.SGD","LU1599440770.SGD","LU0731783048.USD","LU2506952097.USD","AFG","IE00BDGV0183.EUR","IE00BGHQF631.EUR","BK4566","IE00B3T34201.USD","BK4588","LU0950375773.USD","LU2133065610.SGD","LU2089284900.SGD","LU2506952170.USD","IE00B3PB1722.GBP","BK4199","LU0731783394.SGD","LU0823417653.USD","LU2506951958.HKD","LU0158827948.USD","LU0823417737.USD","LU1732800096.USD","LU2023251221.USD","LU0742537680.HKD","BK4107","IE00B42XCP33.USD","LU2506951875.HKD","BK4575","LU0795875169.SGD","BK4561","LU2347655156.SGD","ITP","LU1718418525.SGD","LU2237438978.USD","LU1732799900.SGD","LU0772969993.USD","BNGO"],"gpt_icon":1},{"id":"2519831939","title":"Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2519831939","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519831939?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 21:00","pubTimestamp":1741870800,"startTime":"0","endTime":"0","summary":"In-Motion Webinar: Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implicati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042236/0/en/Bionano-Announces-Publication-Reporting-First-Use-of-OGM-to-Detect-Chromoanagenesis-a-Key-Marker-of-Poor-Prognosis-in-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","LU1571399168.USD","BK4585","BK4524","BK4199","BK4588","ITP","CAG"],"gpt_icon":0},{"id":"2514094330","title":"3 US Penny Stocks With At Least $3M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2514094330","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514094330?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:11","pubTimestamp":1740489075,"startTime":"0","endTime":"0","summary":"As the U.S. markets experience a downturn, with major indices like the S&P 500 and Nasdaq Composite extending their slump, investors are keenly observing how different sectors respond to these shifts. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential value despite their vintage-sounding name. These stocks can offer unique opportunities when they possess strong financial foundations, and in this article, we explore three such penny stocks that stand out for their financial resilience and growth potential.Overview: IT Tech Packaging, Inc. and its subsidiaries produce and distribute paper products in the People’s Republic of China, with a market cap of $3.52 million.Click here to discover the nuances of IT Tech Packaging with our detailed analytical financial health report.Examine IT Tech Packaging's past performance report to understand how it has performed in prior years.Operations: Nu Ride Inc. has not rep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-penny-stocks-least-131115628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BABB","LU1894683348.USD","ARKG","BK4585","BK4544","ITP","BK4209","BK4534","NRT","LU0787776722.HKD","BK4213","LU1894683264.USD","BK4199","LU1093756325.SGD","SB","BK4021","LU0683600562.USD","BK4512","BK4563","LU1093756168.USD","BK4533","PHX","PVL","BK4206","BK4588","MMM"],"gpt_icon":0},{"id":"2514477615","title":"RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514477615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514477615?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 23:09","pubTimestamp":1740409740,"startTime":"0","endTime":"0","summary":"Shares of biotechnology company Rigel Pharmaceuticals, Inc. RIGL have surged 41.4% in the past year against the industry’s decline of 13.4%. The stock also outperformed the sector and S&P 500 Index during this time frame.The outperformance can be attributed to the strong growth of leading drug, Tavalisse, and an impressive pipeline progress.Rigel’s first approved product Tavalisse  showed encouraging uptake in 2024. The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia  who have had an insufficient response to a previous treatment. The drug is also approved in the EU, UK and Japan.Last month, Rigel provided a business update and outlook for 2025. Tavalisse generated $104.8 million in net product sales in 2024.Last month, the FDA granted Orphan Drug designation to R289, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, for the treatment of myelodysplastic syndromes . RIGL is evaluating the candidate in an ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigl-stock-surges-41-4-150900726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BPMC","BK4532","BK4557","BK4199","BK4596","RDY","LU0053671581.USD","BK4523","LU0348744763.USD","ITP","BK4007","BK4505","BK4139","RIGL"],"gpt_icon":0},{"id":"2505670664","title":"Bionano Announces Effective Date of Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2505670664","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505670664?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:05","pubTimestamp":1737579900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan.  22, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/22/3013867/0/en/Bionano-Announces-Effective-Date-of-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2505542747","title":"Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2505542747","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505542747?lang=en_us&edition=full_marsco","pubTime":"2025-01-22 21:05","pubTimestamp":1737551100,"startTime":"0","endTime":"0","summary":"First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor. SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase  inhibitor, in patients with sickle cell disease . The study is being sponsored by the National Heart, Lung, and Blood Institute , part of the National Institute of Health . Fostamatinib, marketed in the U.S. as TAVALISSE  tablets, is approved for the treatment of adult patients with chronic immune thrombocytopenia  who have had an insufficient response to a previous treatment.\"We are excited to support another important study conducted by the NIH/NHLBI for fostamatinib, as they investigate SYK inhibition and its potential to benefit patients with sickle cell disease, a devasting, lifelong condition,\" said Raul ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rigels-fostamatinib-being-studied-national-130500806.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigels-fostamatinib-being-studied-national-130500806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0114720955.EUR","BK4082","GB00B4QBRK32.GBP","BK4139","RIGL","RBC","ITP","SCD","LU1791710582.SGD","LU2362541273.HKD","BK4566","VOC","NHLD","LU0882574055.USD","BK4199","LU2404859667.USD","LU2362541513.USD","BK4585","LU0690374615.EUR","LU2362540622.SGD","SYK","BK4554","BK4548","LU2404859741.USD","LU0528227936.USD","NET","LU2286300806.USD","LU2089984988.USD","BK4161","BK4213","IE00BLDYK493.USD","LU1983299246.USD","BK4560","GB00B4LPDJ14.GBP","BK4504","IE00B64QTZ34.USD","LU2065731478.USD","LU0690374961.EUR","LU2468319806.SGD","BK4116","LU1791710400.SGD","BK4588"],"gpt_icon":0},{"id":"2505267149","title":"Kissei’s Tavalisse Gains Approval in South Korea for Chronic ITP","url":"https://stock-news.laohu8.com/highlight/detail?id=2505267149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505267149?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 10:53","pubTimestamp":1737428039,"startTime":"0","endTime":"0","summary":"Kissei Pharmaceutical Co ( ($JP:4547) ) has issued an update. Kissei Pharmaceutical Co., Ltd. announced that its partner, JW Pharmaceutical Corpora...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kisseis-tavalisse-gains-approval-in-south-korea-for-chronic-itp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kisseis-tavalisse-gains-approval-in-south-korea-for-chronic-itp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2503527011","title":"Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2503527011","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503527011?lang=en_us&edition=full_marsco","pubTime":"2025-01-14 21:00","pubTimestamp":1736859600,"startTime":"0","endTime":"0","summary":"OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical researchers apply targeted screening to select the most fit embryos for transferFollowing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009238/0/en/Bionano-Announces-Use-of-OGM-in-Preimplantation-Genetic-Testing-as-Part-of-Successful-Live-Birth-to-a-Couple-Experiencing-Recurrent-Pregnancy-Loss.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199","BK4121","GENE"],"gpt_icon":0},{"id":"2503094373","title":"Press Release: Rigel Provides Business Update and 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503094373","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503094373?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 21:05","pubTimestamp":1736773500,"startTime":"0","endTime":"0","summary":"-- Preliminary fourth quarter 2024 total revenue of approximately $57.6. REZLIDHIA net product sales of $7.4 million and GAVRETO net product. \"2024 was a transformational year for Rigel as we successfully executed on our corporate strategy to grow our hematology and oncology focused organization. We generated record sales of both TAVALISSE and REZLIDHIA and welcomed a third product to our commercial portfolio, GAVRETO, which made a substantial contribution to our sales in the latter half of the year. This commercial success, combined with our commitment to financial discipline, enabled Rigel to reach financial breakeven, a key milestone for the company,\" said Raul Rodriguez, Rigel's president and CEO. \"In addition, we advanced our development pipeline, with the Phase 1b study of R289 in lower-risk MDS continuing to enroll patients and publishing promising initial safety and efficacy data. Building on this progress, we will continue to implement effective strategies that further grow an","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ASH","BK4232","BK4199","RIGL","R","LU2463526074.USD","ITP","BK4109","BK4139"],"gpt_icon":0},{"id":"2503309963","title":"Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309963","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309963?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over Q4 2023 due primarily to discontinuation of clinical service products in 2024. Installed base of optical genome mapping  systems reached an estimated 371 as of YE 2024, which is an increase of 14% over the 326 installed OGM systems as of YE 2023. Preliminary number of nanochannel array flowcells sold in Q4 2024 expected to be 8,058, which would represent an estimated increase of 1% over the 7,980 flowcells sold in Q4 2023. Q4 2024 Preliminary Unaudited Financial and Business Results. Revenues are expected to grow 30-33% in the fourth quarter of 2024 compared to the $6.1 million in revenues for the third quarter of 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bionano-reports-preliminary-fourth-quarter-130000031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITP","BK4121","BK4199","BK4575","BNGO"],"gpt_icon":0},{"id":"2501751734","title":"Kissei Pharma Partners with Tai Tien for Tavalisse Drug Development, Commercialization in Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501751734","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501751734?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 07:08","pubTimestamp":1736291322,"startTime":"0","endTime":"0","summary":"Kissei Pharmaceutical  has signed a sub-licensing deal with Tai Tien Pharmaceuticals for the development and commercialization of Tavalisse  in Taiwan, according to a Tuesday filing on the Tokyo Stock Exchange.Tai Tien will receive commercialization rights, while Kissei will supply the product and receive upfront and milestone payments.The oral SYK inhibitor, approved in multiple regions, treats chronic idiopathic thrombocytopenic purpura .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ITP","BK4199"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":-0.197},{"period":"3month","weight":-0.3839},{"period":"6month","weight":-0.0519},{"period":"1year","weight":0.1996},{"period":"ytd","weight":-0.5594}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.001343},{"month":2,"riseRate":0.375,"avgChangeRate":0.007233},{"month":3,"riseRate":0.1875,"avgChangeRate":-0.021818},{"month":4,"riseRate":0.3125,"avgChangeRate":0.039592},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.107909},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.040993},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.051814},{"month":8,"riseRate":0.133333,"avgChangeRate":-0.080956},{"month":9,"riseRate":0.4,"avgChangeRate":-0.016928},{"month":10,"riseRate":0.4,"avgChangeRate":0.047355},{"month":11,"riseRate":0.4,"avgChangeRate":0.109469},{"month":12,"riseRate":0.133333,"avgChangeRate":0.004344}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction